Tango Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Tango Therapeutics, Inc. (TNGX) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 87.67 million shares for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-11.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2022-05-11
- Tango Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2022-03-31 was 87.67M shares, a 110.87% increase year-over-year.
- Tango Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-12-31 was 88.24M shares, a 119.50% increase year-over-year.
- Tango Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-09-30 was 70.16M shares, a 100.06% increase year-over-year.
- Tango Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2021-06-30 was 16.68M shares.
- Tango Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2021 was 62.11M shares, a 94.50% increase from fiscal 2020.
- Tango Therapeutics, Inc. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 31.93M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic and Diluted 4 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 7 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|---|---|---|
| 2022-03-31 | 87.67M shares 10-Q · filed 2022-05-11 | 87.96M shares derived: average of 2 quarters · filed 2022-05-11 | 82.02M shares derived: average of 3 quarters · filed 2022-05-11 | 65.69M shares derived: average of 4 quarters · filed 2022-05-11 | |||
| 2021-12-31 | 88.24M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 79.20M shares derived: average of 2 quarters · filed 2022-03-28 | 58.36M shares derived: average of 3 quarters · filed 2022-03-28 | 62.11M shares 10-K · filed 2022-03-28 | |||
| 2021-09-30 | 70.16M shares 10-Q · filed 2021-11-09 | 43.42M shares derived: average of 2 quarters · filed 2021-11-09 | 53.40M shares 10-Q · filed 2021-11-09 | 42.15M shares derived: average of 4 quarters · filed 2022-05-11 | |||
| 2021-06-30 | 16.68M shares 10-Q · filed 2021-08-09 | 16.68M shares 10-Q · filed 2021-08-09 | 32.82M shares derived: average of 3 quarters · filed 2022-05-11 | 33.38M shares derived: average of 4 quarters · filed 2022-05-11 | |||
| 2021-03-31 | 41.58M shares 10-Q · filed 2022-05-11 | 16.68M shares 10-Q · filed 2021-05-14 | 40.89M shares derived: average of 2 quarters · filed 2022-05-11 | 38.95M shares derived: average of 3 quarters · filed 2022-05-11 | |||
| 2020-12-31 | 40.20M shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | 37.64M shares derived: average of 2 quarters · filed 2022-03-28 | 16.68M shares 10-K · filed 2021-03-31 | 31.93M shares 10-K · filed 2022-03-28 | |||
| 2020-09-30 | 35.07M shares 10-Q · filed 2021-11-09 | 16.68M shares 10-Q · filed 2020-11-13 | 16.68M shares 10-Q · filed 2020-11-13 | 29.18M shares 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |